FDA Approves a New Sunscreen Ingredient for the First Time in 20 Years: Bemotrizinol
In this article
On the “UVA Protection Gap”
To understand bemotrizinol's true value, we must distinguish two kinds of sun rays. Ultraviolet (UV) radiation from the sun comes mainly in two forms: UVB and UVA. Both increase skin cancer risk, but in different ways.
☀️ UVB vs UVA: TWO DIFFERENT THREATS
UVB: These are high-energy rays that cause sunburn and promote skin cancer by directly damaging DNA. Most conventional sunscreens protect well against UVB, because SPF (sun protection factor) primarily measures UVB protection.
UVA: These longer-wavelength rays penetrate the skin more deeply . They cause subtle damage without sunburn: premature skin aging — wrinkles and spots —, immune suppression, and, crucially, a higher risk of skin cancers including melanoma. The problem was that many US sunscreens provided inadequate UVA protection.
Bemotrizinol (internationally BEMT; trade names Tinosorb S and Parsol Shield) is a fat-soluble organic (chemical) UV filter. It is broad-spectrum: it protects skin by absorbing both UVA and UVB.
What are chemical (organic) and mineral (inorganic) filters?
Sunscreens use two main filter types. Mineral filters (zinc oxide and titanium dioxide) partly reflect and absorb light and may leave a white cast. Organic (chemical) filters primarily absorb UV light, convert its energy to heat, and release it from the skin. Bemotrizinol is an organic filter, but with an important distinction: it became the first organic filter to receive FDA's “generally recognized as safe and effective” (GRASE) status. Until now, only mineral filters — zinc oxide and titanium dioxide — held that status.
WHAT MAKES BEMOTRIZINOL DIFFERENT?
Photostability: One of its most important advantages. Bemotrizinol stays stable without breaking down in sunlight. This differs importantly from avobenzone, a UVA filter long used in the US: avobenzone degrades with sun exposure, whereas bemotrizinol does not. Bemotrizinol may also help stabilize other filters in the formulation.
Low skin absorption: According to FDA's review, bemotrizinol is minimally absorbed through the skin at concentrations up to 6% and does not enter the bloodstream to a significant extent. This is an important safety advantage at a time when systemic absorption of some older chemical filters has been questioned.
Low irritation: The risk of skin irritation is low, potentially making it more suitable for people irritated by older organic filters, such as octinoxate. It also allows cosmetically more elegant, lightweight formulations without visible residue, reducing the white-cast problem on darker skin tones.
The first question is obvious: why was an ingredient used elsewhere for a quarter-century approved in the US only in 2026? The answer lies in how US sunscreens are regulated.
DRUG OR COSMETIC? THE KEY DIFFERENCE
- The US model: It classifies sunscreen filters as over-the-counter drugs (OTC drugs) . A new filter therefore requires strict clinical evidence and a thorough regulatory process: slow, but data-intensive.
- The model in Europe and many other countries: It classifies sunscreen filters as cosmetics . New technologies can therefore reach the market much faster, though some experts consider the data requirements less stringent.
- The result: US consumers had fewer UV filters to choose from for years; modern filters providing strong UVA protection were absent from US shelves.
Bemotrizinol's safety profile draws on both its long history of international use and the data FDA reviewed.
SAFETY DATA
- Low systemic absorption: Skin absorption is minimal at concentrations up to 6%; average absorption levels are below FDA's threshold for systemic exposure.
- Carcinogenicity study: FDA's review included a 2-year animal study showing no evidence of carcinogenic effects when applied to skin.
- International history: In use since 1999, with about ~27 years of safety experience in Europe, Asia, and Australia. However, some of these countries have less stringent data requirements than the US, so FDA conducted its own review.
- GRASE status: Considered safe and effective for children aged 6 months and older, alongside zinc oxide and titanium dioxide.
The approval was also presented within a current US political framework. FDA and the Department of Health and Human Services (HHS) linked it to a priority in the “Make America Healthy Again (MAHA)” strategy report, which argued that US sunscreen regulation lagged behind other countries and needed modernization. The HHS Secretary and FDA officials framed the decision as a positive step toward modernizing regulation and expanding consumer access.
An objective framework
Whatever the political framing, the scientific point is this: bemotrizinol is a broad-spectrum, photostable UV filter with low absorption that has been used elsewhere for a quarter-century. Its introduction in the US was long supported by the dermatology community, including the American Academy of Dermatology. The approval is therefore defensible scientifically and in public health terms, independently of a particular administration's priorities.
There is an important point for readers in Turkey: bemotrizinol has already been used in Turkey and Europe for years. This approval concerns the US specifically, because the “gap” was a US issue. Since the European Union regulates sunscreen filters as cosmetics, Tinosorb S (bemotrizinol) and similar modern filters have long been available in the European market, including Turkey.
🗣 Proper sun protection: practical reminders
“Even the best sunscreen works only when used correctly. Choose a broad-spectrum product (UVA + UVB) with at least SPF 30; use roughly a handful for the whole body (≈30 ml/1 ounce); apply 15-30 minutes before sun exposure; reapply every 2 hours and after swimming or sweating. No sunscreen is 'waterproof.' Sunscreen alone is not enough — shade, protective clothing, a hat, and sunglasses are also part of skin cancer prevention. See a dermatologist about any new, changing, or non-healing mole or spot.”
⚡ WHY DOES IT MATTER?
Skin cancer is among the most common cancers worldwide and is largely preventable. The quality of UV protection is a direct public health issue. This approval is a step toward closing the US's “UVA gap,” which remained for 20+ years, and a concrete example of regulatory modernization through the CARES Act route. In preventive oncology, effective, usable sun protection is among the most cost-effective cancer prevention tools.
✅ STRENGTHS
Bemotrizinol is photostable — unlike avobenzone, it does not degrade —, broad-spectrum with strong UVA protection, minimally absorbed through skin, and low in irritation risk. It is the first organic filter given GRASE status by FDA. About ~27 years of international use plus FDA's independent review, including a 2-year carcinogenicity study. Cosmetic elegance improves consistent use and therefore real-world protection. The dermatology community supports it.
⚠️ CAUTIONS AND CONTEXT
This is a prevention tool, not a “treatment”; expecting a miracle would be wrong. Approval concerns the US; it is already available in Turkey and Europe. No sunscreen alone is sufficient; behavioral protection such as shade and clothing is essential. International safety experience is strong, but some countries' data standards are lower than the US's, explaining FDA's own review. Political framing (MAHA) must not be confused with scientific assessment.
🩺 IMPLICATIONS FOR PRACTICE
The main message for readers in Turkey is that modern broad-spectrum sunscreens are already available; what matters is correct, consistent use. In oncology and dermatology, sun protection is a basic tool for preventing melanoma and non-melanoma skin cancers. This news is a useful opportunity to reinforce patient education about why UVA protection matters and why regular use is essential.
❓ QUESTIONS FOR THE FUTURE
When will new US bemotrizinol products reach shelves, and how will they be priced? Will the CARES Act route accelerate US access to other modern UV filters, such as bisoctrizole/Tinosorb M? Will better UVA protection produce a measurable long-term reduction in melanoma incidence? Will cosmetic elegance genuinely improve consistent use and therefore protection?
Although FDA's bemotrizinol approval may look like a small regulatory detail, it is a meaningful step in skin cancer prevention and sun protection science. The US's decades-long “UVA protection gap” is moving toward closure with a photostable, broad-spectrum filter used elsewhere for a quarter-century. For Turkey and Europe, this is less a new opportunity than a reminder of the value of existing options and good protection habits. A basic principle of preventive oncology applies here too: the best treatment is one never needed — and for skin cancer, intelligent sun protection makes this possible to a large extent. Bemotrizinol promises both more effective and more pleasant protection, but the real difference depends less on which cream we choose than on how regularly and correctly we use it.
Sources
- U.S. Food and Drug Administration. FDA Expands Sunscreen Options for the First Time in 20 Years (press release). 9 June 2026. Final order: OTC000039 (accessdata.fda.gov).
- FDA. Proposed order to add bemotrizinol to the OTC sunscreen monograph; public comment period 12 December 2025 – 26 January 2026.
- Scientific American. How the new FDA-approved ingredient bemotrizinol enhances sunscreen protection. June 2026. (UVA/UVB mechanisms, organic/inorganic filters, GRASE.)
- Dermatology Times. FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol. (Broad spectrum, minimal absorption, low irritation; AAD support.)
- Healio Dermatology. FDA finalizes action on bemotrizinol, first new active sunscreen ingredient in 20 years. 9 June 2026. (Photostability, cosmetic elegance, dermatologists' assessments.)
- Drug Topics. FDA Approves Bemotrizinol as an OTC Sunscreen Ingredient. (CARES Act route, use recommendations, drug versus cosmetic regulation.)
- Environmental Working Group (EWG). FDA approves first new sunscreen ingredient in 25 years; bemotrizinol BEMT, UVA gap, 2-year animal study, first application in 2005 / DSM application in 2024 / CARES Act. 2026.
- Historical/product context. Bemotrizinol internationally: Tinosorb S (BASF), Parsol Shield (DSM); in use in Europe, Asia, and Australia since 1999.
This article is medical news/review material for information, not individual medical advice. The approval in question — FDA, 9 June 2026 — concerns the US market; bemotrizinol has long been available in sunscreens in Europe, including Turkey, and many other countries, because they regulate UV filters as cosmetics. “FDA approved it” does not mean new access in Turkey. No sunscreen alone provides complete protection against skin cancer; sun protection should also include shade, protective clothing, a hat, and sunglasses. Consult a dermatologist about product choices and individual skin health issues; any new, changing, bleeding, or non-healing skin lesion must be assessed by a physician. This article paraphrases the FDA announcement and dermatology sources and contains no direct quotations. The information reflects the date of preparation.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.